{"title":"Inflammatory Burden Index Prognostic Impact in Patients With Gastric Cancer After Gastrectomy: A Propensity Score-matched Analysis.","authors":"Itaru Hashimoto, Yuta Nakayama, Mie Tanabe, Jyunya Morita, Shinsuke Nagasawa, Yukio Maezawa, Kyohei Kanematsu, Toru Aoyama, Takanobu Yamada, Norio Yukawa, Yasushi Rino, Aya Saito, Takashi Ogata, Takashi Oshima","doi":"10.21873/anticanres.17228","DOIUrl":null,"url":null,"abstract":"<p><strong>Background/aim: </strong>The Inflammatory Burden Index (IBI) has been reported as a novel prognostic indicator in several cancers and diseases. However, research on the IBI in patients with gastric cancer (GC) after gastrectomy is insufficient. This study investigated the utility of the preoperative IBI as a prognostic indicator in patients with GC.</p><p><strong>Patients and methods: </strong>This retrospective study enrolled 459 patients undergoing gastrectomy for GC between 2013 and 2017 at the Kanagawa Cancer Center, Kanagawa, Japan. The IBI was calculated from preoperative blood test data. We evaluated the relationship between the preoperative IBI and clinicopathologic factors, overall survival (OS), and recurrence-free survival (RFS) after gastrectomy for GC, using propensity score matched analysis.</p><p><strong>Results: </strong>Regarding the association between IBI and clinicopathologic features, the high-IBI group was significantly older and had more lymphatic invasion and more progressive pT status than the low-IBI group before propensity score-matched analysis. OS and RFS after curative surgery were significantly lower in patients with a high IBI than in those with a low IBI (77.5% vs. 86.1%; p=0.02 and 74.3% vs. 85.1%; p=0.03, respectively). Multivariate analysis identified high IBI as an independent predictor of both OS and RFS.</p><p><strong>Conclusion: </strong>Preoperative IBI may serve as a valuable prognostic indicator for patients undergoing curative gastrectomy for GC.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":null,"pages":null},"PeriodicalIF":1.6000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anticancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/anticanres.17228","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background/aim: The Inflammatory Burden Index (IBI) has been reported as a novel prognostic indicator in several cancers and diseases. However, research on the IBI in patients with gastric cancer (GC) after gastrectomy is insufficient. This study investigated the utility of the preoperative IBI as a prognostic indicator in patients with GC.
Patients and methods: This retrospective study enrolled 459 patients undergoing gastrectomy for GC between 2013 and 2017 at the Kanagawa Cancer Center, Kanagawa, Japan. The IBI was calculated from preoperative blood test data. We evaluated the relationship between the preoperative IBI and clinicopathologic factors, overall survival (OS), and recurrence-free survival (RFS) after gastrectomy for GC, using propensity score matched analysis.
Results: Regarding the association between IBI and clinicopathologic features, the high-IBI group was significantly older and had more lymphatic invasion and more progressive pT status than the low-IBI group before propensity score-matched analysis. OS and RFS after curative surgery were significantly lower in patients with a high IBI than in those with a low IBI (77.5% vs. 86.1%; p=0.02 and 74.3% vs. 85.1%; p=0.03, respectively). Multivariate analysis identified high IBI as an independent predictor of both OS and RFS.
Conclusion: Preoperative IBI may serve as a valuable prognostic indicator for patients undergoing curative gastrectomy for GC.
背景/目的:据报道,炎症负担指数(IBI)是多种癌症和疾病的新型预后指标。然而,有关胃切除术后胃癌(GC)患者炎症负担指数的研究尚不充分。本研究调查了术前 IBI 作为胃癌患者预后指标的实用性:这项回顾性研究纳入了 2013 年至 2017 年期间在日本神奈川县神奈川癌症中心接受胃切除术的 459 例 GC 患者。IBI根据术前血液检测数据计算得出。我们采用倾向得分匹配分析法评估了术前IBI与GC胃切除术后临床病理因素、总生存期(OS)和无复发生存期(RFS)之间的关系:关于IBI与临床病理特征之间的关系,在倾向得分匹配分析前,高IBI组的年龄明显大于低IBI组,且高IBI组的淋巴侵犯更多,pT状态更进展。高IBI组患者治愈性手术后的OS和RFS明显低于低IBI组(分别为77.5% vs. 86.1%;P=0.02和74.3% vs. 85.1%;P=0.03)。多变量分析发现,高IBI是OS和RFS的独立预测因素:结论:术前IBI可作为GC根治性胃切除术患者有价值的预后指标。
期刊介绍:
ANTICANCER RESEARCH is an independent international peer-reviewed journal devoted to the rapid publication of high quality original articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months of acceptance are guaranteed.
ANTICANCER RESEARCH was established in 1981 and is published monthly (bimonthly until the end of 2008). Each annual volume contains twelve issues and index. Each issue may be divided into three parts (A: Reviews, B: Experimental studies, and C: Clinical and Epidemiological studies).
Special issues, presenting the proceedings of meetings or groups of papers on topics of significant progress, will also be included in each volume. There is no limitation to the number of pages per issue.